1Wendling F, Marskovsky E, Debili N, Florindo C, et al. (1994) ligand is a humoral regulator of megakaryopoiesis. Nature 369:571.

2Wendling F, Marskovsky E, Debili N, Florindo C, et al. (1994) ligand is a humoral regulator of megakaryopoiesis. Nature 369:571.

3Sohma Y, Akahori H, Seki N. Hori T, Ogami K, et al. (1994) Molecular cloning and chromosomal location of thrombopoietin. FEBS Lett 353:57.

4Yan XD, Lacey D, Hill D et al. (1996) A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand); reversal of disease by bone marrow transplantation. Blood 88:402-409.

5Villeval JL, Cohen-Solal K, Tulliez M, Giraudier S, et al. (1997) High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 90:4369-4383.

6Vannuccihi A, Bianchi L, Paoletti F, Pancrazzi A, Torre E, Nishikawa M, Zingariello M, et al. (2005) A pathobiologic pathway linking thrombopoietin GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood 105:3493-3501.

7Schlemper RJ, van der Maas APC, Eikenboom JCJ, et al. (1994) Familial essential thrombocythemia: clinical characteristics of 11 cases in one family. Ann Hematol 68:153-158.

8Wiestner A, Schlemper RJ, van der Maas APC, Skoda RC, et al. (1998) An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia. Nat Genet 18:49-52.

9Kondo T. Okabe M, Sanada M, Kurosawa M, Suzuki S, Kobayashi M, et al. (1998) Familial essential thrombocythemia associated with a one-base deletion in the 5'-untranslated region of the thrombopoietin gene. Blood 92:1091-1096.

10Michiels JJ, Abels J, Steketee J, Vuzevski VD, et al. (1985) Erythromelalgia caused by platelet mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 102:466-471.

11MichielsJJ, Juvonen E (1997) Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group (TVSG). Semin Thromb Hemostas 23:339-347.

12Ellis JT Silver RT, Coleman, Geller SA (1975) The bone marrow in polycythemia vera. Semin Hematol 12:433-444.

13Kralovics R, Buser AS, Teo SS, Coers J, Tchelli A, et al. (2003) Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 102:1869-1871.

14Liu K, Kralovics R, Ridzli Z, Grabovsky B, Buser AS, et al. (2008) A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica 93:706-714.

15Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, et al. (2006) The 2001 World Health Organization (WHO) and updated European Clinical Molecular and Pathological (2006 ECMP) criteria for the diagnosis classification and staging of the Philadelphia-negative chronic myeloproliferative disorders. Sem Thromb Hemostas 32:307-340.

16Michiels JJ, Ten Kate F, Lam KH, Schroyens W, et al. (2014) The European clinical, Molecular and Pathological (ECMP) criteria and the 2007/2008 revision of the World Health Organization (WHO) for the diagnosis, classification and staging of prefibrotic myeloproliferative neoplasms carrying the JAK2V617F mutation. Turk J Hematol 31:239-254.

17Posthuma HLA, M, Skoda RC, Jacob FA, Van der Maas APC, et al. (2010) Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis. Blood 110:3375-3376.

18Michiels JJ, Berneman Z, Schroyens W, Lam KH, De Raeve H (2013) PVSG versus WHO and European Clinical, Molecular and Pathological criteria for prefibrotic myeloproliferative neoplasm. World J Hematol 2:71-88.

19Michiels JJ, Berneman Z, Schroyens W, De Raeve H (2015) Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: From Dameshek 1950 to Vainchenker 2005 and beyond. Acta Haematol 133:71-86.

20Michiels JJ, Valster F, Wielenga J, Schelfout K, De Raeve H (2015) European vs 2015 World Health Organization clinical molecular and pathological classification of myeloproliferative neoplasms. World J Hematol 4:16-53.

21Georgii A, Vykoupil KF, Thiele J (1980) Chronic megakaryocytic granulocytic myelosis–CMGM. A subtype of chronic myeloid leukemia. Virchovs Archive A 389:253-268.

22Michiels JJ, Thiele J (2002) Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 76:133-145.

23ThieleJ, Kvasnicka HM, Zankovich R, Diehl V (2001) Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann Hematol 80:160-165.

24Mead AJ, Rugless MJ, Jacobsen SE, Schuh A (2012) Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med 366: 967-969.

25Mead AJ, Chowdhury O, Pecquet C, Dusa A, et al (2013) Impact of isolated germline JAK2V617I mutation on human hematopoiesis. Blood 121:4156-4165.

26Etheridge SL, Cosgrove ME, Sangkhae V, Corbo LM, Roh ME, et al. (2014) A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood 123: 1059-1068.

27Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, et al. (2004) Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103:4198–4200.

28Teofili L, Giona F, Torti L, Cenci T, Ricerca BM, et al. (2010) Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica 95:65–70.

29Pardanani A, Levine RL, Lasho TL et al. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108:3472-3476.

30Pikman Y, Lee BH, Mercher Th et al. (2006) MPLW515L is a novel somatic activation mutation in myelofibrosis with myeloid metaplasia. PLOS Med 3:e270.

31Vannucchi AM, Antonioli E, Guglielmelli P, et al. (2008) and Barbui T. Characteristics and clinical correlates of MPL515W>L/K mutation in essential thrombocythemia. Blood 112:844-847.

32Schnittger S, Bacher U, Haferlach C Haferlach T, et al. (2008) Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica 94:141-144.

33Chaligne R, James C, Tonetti C, et al. (2007) Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 110:3735-3743.

34Michiels JJ, Ten Kate F, Lam KH, Schroyens W, Berneman Z, De Raeve H (2014) The European Clinical, Molecular and Pathological (ECMP) criteria and the 2007/2008 revision of the World Health Organization for the diagnosis, classification and staging of prefibrotic myeloproliferative neoplasms carrying the JAK2V617F mutation. Turk J Hematol 31:239-254.

35Michiels JJ, De Raeve H, Schwarz J, Campr V, Kim Y, Kim M (2018) Bone marrow histology characteristics in MPL515 mutated Thrombocythemia with various degrees of myelofibrosis: a cross-sectional follow-up study in eight cases, J Hematol Thromb Dis 6:2.

36Klampf T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379- 2387.

37Michiels JJ, Prins MEF, Hagemeijer A, Brederoo, P, et al. (1987)Philadelphia chromosome-positive essential thrombocythemia and megakaryoblast leukemia. Am J Clin Pathol 88:645-752.

38Michiels JJ, Berneman Z, Schroyens W, Kutti J, Swolin B, et al. (2004) Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood and bone marrow: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. Ann Hematol 83:504-512.

39Michiels JJ, Ten Kate FWJ, De Raeve H, Gadisseur A (2015) Bone marrow features and natural history of BCR/ ABL positive thrombocythemia and chronic myeloid leukemia compared to BCR/ABL negative thrombocythemia in essential thrombocythemia and polycythemia vera. J Hematol Thromb Dis 3:2.

40Vainchenker W, Kralovics R (2017) Genetic basis and molecular pathogenesis of classical myeloproliferative neoplasms. Blood 129:667-679.